Comparative Pharmacology
Head-to-head clinical analysis: DIMENHYDRINATE versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMENHYDRINATE versus ZUPLENZ.
DIMENHYDRINATE vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimenhydrinate is a histamine H1 antagonist with central anticholinergic activity. It acts by blocking H1 receptors in the brain's vomiting center and inhibiting vestibular stimulation. It also has anticholinergic effects by binding to muscarinic receptors, reducing motion sickness.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
50-100 mg orally or intramuscularly every 4-6 hours as needed; maximum 400 mg per day. For motion sickness, 50-100 mg 30 minutes before travel.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
Clinical Note
moderateDimenhydrinate + Venlafaxine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Venlafaxine."
Clinical Note
moderateDimenhydrinate + Nefazodone
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nefazodone."
Clinical Note
moderateDimenhydrinate + Stiripentol
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Stiripentol."
Clinical Note
moderateTerminal elimination half-life is 5-10 hours in adults, longer in elderly or hepatic impairment (up to 15 hours).
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Primarily renal, with 60-80% of the dose excreted unchanged in urine; minor biliary/fecal elimination accounts for <10%.
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category C
Category C
Antiemetic
Antiemetic
Dimenhydrinate + Clomipramine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clomipramine."